# FDA Update

Clinical Laboratory Improvement Advisory Committee Meeting September 5, 2007

**Alberto Gutierrez** 

Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health US Food and Drug Administration





- Organizational Changes
- FDA Guidance Update
- User Fee Update
- Pre-Market Update
- Post-Market Update



# Organizational Changes

- New Center Deputy Director
  Mark Raza
- New Office Deputy Director
  Alberto Gutierrez
- New/Old Division Director for Chemistry and Toxicology
  - Jean Cooper
- Return of Liz Mansfield as Senior Policy Advisor



### • IVDMIA

- → First Draft Published Sept. 2006
- → 180 Day Comment Period
- $\rightarrow$  Public meeting to discuss issues
- → Second Draft Published July 2006

### • ASR

- → First Draft Published Sept. 2006
- → 180 Day Comment Period



- Assayed and Unassayed Quality Control Material
- Pharmacogenetic Tests and Genetic Tests for Heritable Markers
- Review Criteria for Assessment of Qualitative Fecal Occult Blood In Vitro Diagnostic Devices
- In Vitro Diagnostic Devices to Detect Influenza A Viruses: Labeling and Regulatory Path



### Class II Special Controls

- Gene Expression Profiling Test System for Breast Cancer Prognosis
- Antimicrobial Susceptibility Test (AST) Systems
- Herpes Simplex Virus Types 1 and 2 Serological Assays



• CLIA Waiver Guidance – Working its way through the system.



## User Fee Update

#### • MDUFMA II

- →Specific OIVD Goals
  - o Guidance Commitments
  - o Performance Goals for CLIA Waiver Petitions
  - o Pilot Study for Co-review of PMA/510(k) and CLIA Waiver
  - o Re-classification of Class II and Class I devices
  - o Clear Path for Review of Molecular Diagnostic Tests



# Pre-Market Update

- Veridex Metastatic Breast Cancer
- Binax NOW Malaria
- 7 Day Continuous Glucose Sensor



# Post-Market Update

- Post-Market Transformation
- Lab Net

→ Few Signals but significant identified
 → OIVD actively calling the laboratories that have joined